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ABSTRACT
Background: The proportion of  persons who become 
infected with resistant strains of  HIV may be increasing. 
We assessed the efficacy of  first line anti-retroviral (ARV) 
regimens since they were first introduced in Nigeria.
Methods: A descriptive prospective cohort study 
comparing baseline body mass index (BMI), CD+4 counts 
thand viral load (VL) with those obtained at 6  month of  
highly active antiretroviral therapy (HAART) in 300 HIV 
infected treatment-naive patients. Data were analysed with 
Epi-Info version 3.3 software and a probability value < 0.05 
was considered significant. 
2Results: The mean BMI at baseline of  22.9±4.6 kg/m  
2 thincreased to 24.6±4.4 kg/m  at 6  month of  HAART. 
Therefore, the absolute increase in mean BMI was 
21.7kg/m  and was statistically significant p<0.05. The 
median CD4+ counts at baseline and at the end of  the 
study shows counts of  127 cells/µl and 236 cells/µl 
respectively. This corresponds to a median increase of  109 
cells/µl but was not statistically significant p=>0.05.  
When immunological response was measured as an 
increase from baseline of  at least 50cells/µl, the proportion 
of  patients with CD4+ count increase = 50cells/µl at the 
sixth month of  HAART was 68%. The baseline median 
viral load was log 4.90, log (IQR 3.41-6.41) but became 10 10
thless than log 2.60, log (IQR 2.60-5.26) at 6  month of  10 10
HAART. Hence, a median viral load reduction of  at least 
log 2.30 p<0.05 was achieved.  10
Conclusion: This study supports the belief  that using 
limited ARV regimens can result in acceptable treatment 
outcomes many years after they were first introduced. 
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agents. In 1999 however, the national AIDS treatment 
programme geared towards expanding access to 
3antiretroviral drugs was instituted  and was followed by 
rapid scale-up in the subsequent years. Currently, nearly 
30% of  about 860,000 HIV/AIDS patients requiring 
treatment in Nigeria are receiving highly active 
antiretroviral therapy (HAART) according to the WHO 
2006 criteria for initiating ART; a significant, though 
inadequate, increase when compared with ART coverage 
1,4of  5% about ten years ago .  
As ART becomes widespread in a given area, one might 
expect an increase in the proportion of  patients who 
become infected with drug resistant strains. The extent to 
which resistant HIV will be transmitted depends on many 
factors, but the most important is ART use (ART coverage 
in an area, duration of  ART use and number of  patients on 
5,6failing regimen) . While most resistance to antiretrovirals 
(ARVs) will be acquired, resistance against antiretroviral 
drugs in previously untreated HIV-positive patients 
(primary drug resistance) is of  growing relevance. It is 
characterized by reduced drug susceptibility in phenotypic 
testing or the presence of  resistance-associated mutations 
in genotypic testing in subjects who were never exposed to 
antiretroviral compounds. The reason for this 
[7]phenomenon is infection with resistant virus strains,  as 
[8] [9] [10]described for sexual,  vertical,  and parenteral  path of  
transmission. For instance, ten years following the ART 
scale-up in Kampala, a repeated survey showed that 8.6% 
of  newly HIV infected patients had mutations associated 
with resistant strains and likely represented an increase 
11from a previous survey . Consequently, clinical and 
laboratory measures of  ART efficacy could be inferior in 
treatment-naive patients following widespread use of  ART 
after a significant period of  time.  
In this study, we evaluated the efficacy of  the commonly 
used first line ARVs in treatment-naive HIV infected 
patients following widespread use of  ARVs. Our primary 
measures were body mass index (BMI), CD4+ cell counts 
and viral loads (VL) at baseline and six months of  HAART. 
METHODS
This was a prospective cohort study that was carried out at 
the Jos University Teaching Hospital (JUTH) to determine 
the efficacy of  first line HAART in treatment-naïve HIV 
infected patients. Clinical response was measured as 
increase in body mass index (BMI); Immunologic response 
was measured as increase in median CD4+ and proportion 
of  patients with CD4+ increases =50cells/µl from baseline 
while the virologic control was measured as log decrease in 
median viral load and proportion of  patients with 
INTRODUCTION
According to the estimate from the Joint United Nations 
Programme on HIV/AIDS (UNAIDS), about 33.3 million 
people were living with HIV/AIDS worldwide with an 
estimated 22.5 million in Sub-Saharan Africa by the end of 
1 22009 . Nigeria reported her first HIV/AIDS case in 1986  
and current estimates put Nigeria's HIV/AIDS prevalence 
at 3.6% in 2007 with over 300,000 new infections occurring 
1in 2008 . In absolute numbers, nearly 3 million people live 
with HIV/AIDS in Nigeria. Early in the evolution of  
HIV/AIDS epidemic in Nigeria, anti-retroviral therapy 
(ART) was minimal and often initiated with single or dual 
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undetectable viral load after commencement of  HAART. 
The study was conducted between November, 2006 and 
April, 2007.
Three hundred consecutive treatment-naïve patients who met 
inclusion criteria where studied. Patients included were 18 
years and above, had confirmed HIV infection by Western 
 Blot and were eligible for ART according to 2005 Nigerian 
12guideline . We excluded patients already on ART and those 
less than 18 years of  age.
The study was approved by the Research and Ethics 
Committee of  JUTH, Jos. All the participants signed an 
appropriate informed consent form before enlisting for the 
study 
The patients were followed up over a period of  six months on 
tablets of  Lamivudine(3TC) 150mg twice daily, 
Stavudine(d4T) 40mg twice daily, Nevirapine(NVP) 200mg 
daily for two weeks then twice daily if  no Nevirapine side 
effect was observed. This was the commonest first line 
HAART regimen. Patients less than 60kg body weight were 
given Stavudine 30mg twice daily. Any other HAART 
regimens were noted. Patients were counselled on adherence 
and drug pick-ups were checked in the pharmacy 
computerized data-base. Complicating diseases were 
recorded together with therapeutic interventions.
Laboratory investigations were done according to the 
12national guidelines.  CD4+ lymphocytes were counted using 
Flow cytometry with CD4 Easy Count kit-CY-R-1004 while 
Viral Load was determined using Polymerase Chain 
Reaction(PCR) technology with Amplicor HIV-1 Monitor® 
Test, Version 1.5 (Lower limit of  detection <400 copies/µl).
Those positive for hepatitis B surface antigen or hepatitis C 
antibody were assumed to have hepatitis infection.
The Epi-Info Version 3.3 2004 statistical software was used 
for statistical analysis. Results were presented as median for 
skewed variables and means ± standard deviation (SD), and 
2tables. The Chi-square(X ) test was used to test proportions of  
categorical variables and a p value of  < 0.05 was considered 
significant.
RESULTS
A total of  300 patients were enrolled into the study but 
292(97.3%) patients completed the study. Five patients 
discontinued due to hepatotoxicity (two were concurrently 
on anti-tuberculosis therapy), two patients because of  severe 
muco-cutaneous reactions and one patient was lost to follow-
up.
The characteristics of  the study population is shown in table 
1.The patients were predominantly middle aged(37.8±6.8 
years) females(64.7%) and mostly on 3TC, d4T, NVP(84%) 
with 96% treatment adherence. There were 48% of  patients 
with assumed hepatitis infection and another 15% with 
tuberculosis (TB).
The results of  our clinical and laboratory measures of  ART 
efficacy are shown in table II. 
2 The mean BMI at baseline was 22.9±4.6 kg/m . At six 
2months on HAART, mean BMI was 24.6±4.4 kg/m . 
Therefore, the mean increase in BMI from the beginning of  
2HAART to six months was 1.7kg/m  and was statistically 
significant p<0.05.
The median CD4+ counts at baseline and at the end of  the 
study shows counts of  127 cells/µl and 236 cells/µl 
respectively. This corresponds to a median increase of  109 
cells/µl but there was no statistically significant difference in 
median CD4+ at 6 months of  HAART compared with 
baseline median CD4+ p=>0.05.  When immunological 
response was measured as an increase from baseline of  at 
least 50cells/µl, the proportion of  patients with CD4+ count 
increase = 50cells/µl at the sixth month of  HAART was 68%. 
The comparison of  median CD4+ cells of  patients with TB to 
their counterparts without TB at baseline and at 6 months did 
not show statistically significant difference in median CD4+ 
counts. For instance, median CD4+ count at baseline was 114 
cells/µl in those with TB and 125 cells/µl in those without TB 
(p=0.13), and 220 cells/µl in those with TB and 231 in those 
without TB (p=0.20) at sixth month of  HAART.
At baseline, the median viral load and range expressed in 
log copies/ml was log 4.90, log (IQR 3.41-6.41). At the 10 10 10
end of  the study period, median viral load was less than log10 
2.60, log (IQR 2.60-5.26). In conventional figures, the 10
baseline median viral load of  90,010 copies/ml reduced to 
less than 400 copies/ml at six months of  HAART. Hence, a 
median viral load reduction of  at least log 2.30 was recorded 10
at sixth month of  HAART.  While all patients had detectable 
viral load at baseline, 80% had undetectable viral load at the 
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Table I. Patients socio-demographic and clinical characteristics 
 
Sex
male                                 35.3 
 
   female                                     64.7 
 
CDC stage  
A                                           37 
    B                                              51 
    C                                         22
 
HIV transmission  
Heterosexual                                   93 
    Other                                     7  
 
Tuberculosis (TB) co-Infection(%)              15.3  
 
Hepatitis co-infection(%) 
    aHBsAg                                    25.3 
    bHCV anti-body                   23 
    a & b                                    2.3 
 
ART regimen  
   3TC + d4T + NVP                83.6 
   3TC + d4T + EFV                15.7 
   3TC + ABC + AZT               0.7 
 
ART adherence(%)       96 





end of  the study. 
DISCUSSION
Effective HAART therapy leads to sustained suppression of  
viraemia and re-population of  CD4+ T-lymphocytes which 
is associated with decreased risk of  opportunistic infections, 
13-16hospitalization and mortality .
The results of  this study showed that first line ARV regimens 
are still efficacious in treatment-naive HIV/AIDS patients 
years after scale-up and widespread use of  ARVs. A 
17preliminary report  on the Nigerian antiretroviral 
programme indicated that between baseline and six months, 
the median viral load was reduced by 1.7log10 copies/ml and 
the median CD4+ count was increased by 140 cells/µl while 
2median body mass index increased by 1.2kg/m , and are in 
support of  our findings.  
The efficacy of  first line ARV regimens in this study was 
2shown by increase in BMI of  1.7kg/m  at the end of  the study 
2period which is comparable to BMI increase of  1.2kg/m  at 6 
17months reported by Idigbe et al  who studied 50 patients 
preparatory to ART programme scale-up in Nigeria; they 
were on a regimen most patients (83.6%) in this study 
received. The increase in BMI noted in our patients could be 
accounted for by the reduced frequencies of  opportunistic 
infections and better nutritional tolerance following effective 
15,18HAART as previously described . 
In this study, the median CD4+ count of  236 cells/µl at the 
sixth month of  HAART was not significantly higher than 
baseline median CD4+ count of  127 cells/µl p=>0.05. While 
17our finding is still comparable to that of  Idigbe et al , the non-
significant increase of  109 cells/µl could be attributed to the 
rather short duration of  this study; since it may take two years 
19to fully assess the extent of  immunologic recovery , a time 
frame beyond the scope of  this study. In terms of  proportion 
of  patients who achieved CD4+ increase = 50cells/µl, 68% of  
our patients had CD4+ counts = 50cells/µl above their 
baseline values at the end of  the study. This CD4+ cell 
recovery might prove clinically relevant because an increase 
of  50 CD4+cells/ìL during the first 6 months of  starting 
potent antiretroviral therapy is associated with a 68% 
20decrease in any AIDS-related opportunistic illness .  In this 
study, co-Infection with TB and hepatitis viruses did not 
significantly impair immunologic recovery. This may have 
been because patients were already on anti-TB for variable 
durations at enrolment, and active hepatitis infection could 
not be established based on HBsAg and HCV antibody 
positivity.
Plasma viral load assay is a critical component for evaluating 
ART efficacy. The median viral load reduction was at least 
log 2.30, and 80% of  our patients had undetectable viral load 10
at the end of  the study. Broadly, our result is consistent with 
21that of  Phillips et al  in which 85 to 90% of  patients had 
undetectable viral load depending on their baseline CD4+ 
and VL counts using <500 viral copies/µl as lower limit of  
detection over a 32 week period. Our finding, however, 
22contrasts that of  Garcia et al  in which about 80% had 
undetectable VL within 12 weeks of  initiating HAART. This 
observation could have been due to differences in sample size 
and the ART regimen with our study. 
Our study has important limitations and the findings thereof  
should be put in context. For example, we did not perform 
ARV resistance assay on those patients who failed to achieve 
adequate CD4+ count increases and virologic suppression. 
In addition, our measures of  efficacy, especially CD4+ 
counts and VL were assessed only twice and are therefore 
unable to isolate any transient changes from true lack of  
treatment efficacy.
In conclusion, our study demonstrates that first line ARVs are 
still efficacious and supports the notion that a public health 
approach using limited ART regimens can result in 
acceptable treatment outcomes even many years after they 
were first introduced. Nevertheless, vigilance against 
degradation of  efficacy, which may be inevitable over time, is 
needed to avert this danger. 
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